Key Takeaways
- • Michael Novogratz, former Goldman Sachs partner and hedge fund manager, predicts psychedelics will become the next "short-term bubble," citing strong positive market sentiment and early-stage therapeutic promise across multiple disease indications.
- • Novogratz has backed Compass Pathways, a UK-based biotech developing psilocybin-derived drugs, and publicly predicted the company will achieve a public offering before year-end 2020.
- • Compass Pathways raised $32 million in a Series A funding round in October 2018 and counts Tom Insel (former National Institutes of Mental Health director) and David Nutt (former UK government drug czar) among its advisors, signaling institutional credibility in the space.
- • Leading research institutions including Johns Hopkins are actively studying psychedelic compounds—psilocybin, MDMA, ketamine—for therapeutic applications in depression, obesity, Alzheimer's disease, and smoking cessation, validating the scientific foundation for commercial development.
- • Novogratz characterizes the current moment as an opportune entry point for early-stage investors to "ride the wave up" in emerging psychedelic drug compounds, drawing parallels to his earlier assessment of the cannabis sector.
Summary
Michael Novogratz, the prominent investor and former Goldman Sachs partner, outlined his thesis for psychedelics as an emerging investment bubble at the Context Summits conference in Miami, positioning the sector as the successor to cannabis-driven market enthusiasm. Speaking at the Fontainebleau Hotel on South Beach, Novogratz stated: "I'm positive this will be the next short-term bubble because it's such a positive story." His conviction is backed by personal capital allocation—he has invested in Compass Pathways, a UK-based biotech company developing therapeutics derived from psilocybin, the active compound in magic mushrooms.
Novogratz projected that Compass Pathways will complete an initial public offering before the end of 2020. A company spokesperson confirmed to Business Insider that the firm is "always looking at options to ensure continued growth and funding" but declined to comment on specific timing speculation. The company's most recent disclosed funding event was a $32 million Series A round closed in October 2018, according to Crunchbase data. The startup has assembled high-profile scientific advisors, including Tom Insel, former director of the National Institutes of Mental Health, and David Nutt, the former UK government drug czar, lending institutional credibility to its research agenda.
The investment thesis rests on expanding clinical validation of psychedelic therapeutics. Leading academic institutions, notably Johns Hopkins, have launched research programs examining psilocybin, MDMA, ketamine, and related compounds for treating depression, obesity, Alzheimer's disease, and smoking cessation. While the science remains early-stage, the convergence of regulatory openness, institutional research backing, and growing acceptance of these "old drugs" and "old plants"—including ayahuasca and African Iboga root—has created what Novogratz views as a favorable risk-reward environment. He frames the current period as an optimal window for investors to establish positions in emerging psychedelic drug development before anticipated market expansion.
Novogratz projected that Compass Pathways will complete an initial public offering before the end of 2020. A company spokesperson confirmed to Business Insider that the firm is "always looking at options to ensure continued growth and funding" but declined to comment on specific timing speculation. The company's most recent disclosed funding event was a $32 million Series A round closed in October 2018, according to Crunchbase data. The startup has assembled high-profile scientific advisors, including Tom Insel, former director of the National Institutes of Mental Health, and David Nutt, the former UK government drug czar, lending institutional credibility to its research agenda.
The investment thesis rests on expanding clinical validation of psychedelic therapeutics. Leading academic institutions, notably Johns Hopkins, have launched research programs examining psilocybin, MDMA, ketamine, and related compounds for treating depression, obesity, Alzheimer's disease, and smoking cessation. While the science remains early-stage, the convergence of regulatory openness, institutional research backing, and growing acceptance of these "old drugs" and "old plants"—including ayahuasca and African Iboga root—has created what Novogratz views as a favorable risk-reward environment. He frames the current period as an optimal window for investors to establish positions in emerging psychedelic drug development before anticipated market expansion.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.